Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker
June 30, 2011
Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker
The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug
December 2, 2010 / Gene Silencing News - Undisclosed Pharma to Evaluate Silence siRNA-Delivery Technology
September 29, 2011 / Gene Silencing News - Amid Delivery Tech Dispute, Alnylam Forges Collaboration with Precision NanoSystems
April 21, 2011 / Gene Silencing News - EGEN Aims to Use 'Bottom-Up' Approach for RNAi Drug-Development Programs
August 5, 2010 / Gene Silencing News - Quark, Nitto Denko Collaborate on RNAi Drugs for Fibrotic Disease
July 15, 2010 / Gene Silencing News